“We have heard a clear message from a number of the trial investigators that they would like to continue avicursen treatment for some of their patients beyond the formal completion of the trial,” commented Percheron CEO, Dr James Garner. “The team has worked closely with the sites and with external advisors to make this possible, and we expect to be able to provide supply to patients who choose to continue, and whom investigators feel may benefit from doing so, free of charge, for a period of time after their participation in the trial concludes. We are grateful to the investigators, the patients and their families for their continuing interest in avicursen.”
Thats a cracking sign
Ann: Percheron launches post-trial access program, page-7
Add to My Watchlist
What is My Watchlist?
